Filtered By:
Drug: Xolair
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
Long-term outcome of omalizumab-assisted desensitisation to cow's milk and eggs in patients refractory to conventional oral immunotherapy: real-life study
CONCLUSIONS: Omalizumab allows desensitisation of children with severe allergies to cow's milk and/or egg without developing severe reactions while receiving this treatment. However, discontinuation of OMZ leads to severe allergic reactions, and hence must be monitored carefully.PMID:35527650 | DOI:10.15586/aei.v50i3.537
Source: Allergologia et Immunopathologia - May 9, 2022 Category: Allergy & Immunology Authors: Roser Ayats-Vidal Silvia Riera-Rubi ó Laura Valdesoiro-Navarrete Miguel Garc ía-González Helena Larramona-Carrera Oscar Asensio-De la Cruz Montserrat Bosque-Garc ía Source Type: research
Treatment of indolent and advanced systemic mastocytosis
Management of Indolent and Smoldering SM is focused on preventing anaphylactic reactions, identifying and avoiding symptom triggers. Skin and gastrointestinal symptoms are managed with H1- and H2-antihistamines. When skin symptoms are not adequately controlled, leukotriene antagonists and oral psoralen combined with ultraviolet therapy may be added. Proton pump inhibitors, sodium cromolyn and oral corticosteroids may be added for gastrointestinal symptoms. Patients should be prescribed with self-injectable epinephrine and trained to treat recurrent cardiovascular symptoms or anaphylaxis. Depression and cognitive impairment...
Source: Mediterranean Journal of Hematology and Infectious Diseases - April 28, 2022 Category: Hematology Authors: Dr. Alessandro Buonomo, Dr. Eleonora Nucera, Dr. Marianna Criscuolo Source Type: research
Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
Source: Journal of Asthma and Allergy - April 20, 2022 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps
AbstractBiological therapies are available for the treatment of the severe allergic asthma (SAA) with blood eosinophil count ≥ 0.3 × 109/L. Several of them also showed benefits on nasal polyps (NP), one of the most frequent comorbidities of the severe asthma, but comparative studies on their effectiveness in the association SAA-NP are currently lacking. The aim of this study is to compare the effectiveness of benralizumab, mepolizumab and omalizumab in patients with SAA-NP in real-life settings. A retrospective, observational, multicenter real-life study was realized including patients with SAA-NP treated by be...
Source: Clinical Reviews in Allergy and Immunology - April 14, 2022 Category: Allergy & Immunology Source Type: research
